retatrutide clinical trial status Michael Weintraub, MD on X: "Looking forward to when #retatrutide's Phase 3 results will become available. There are are 4 planned TRIUMPH trials investigating retatrutide's efficacy in treating obesity and its Retatrutide, an investigational triple hormone

However, sometimes the opposite is true

This is particularly important given the dosing schedule and potential side effects associated with starting and stopping GLP-1 drugs

Not getting enough fluids may make constipation worse instead of better

In clinical trials, nausea was reported by approximately 29-33% of participants, diarrhea affected 21-23% of patients, constipation occurred in 17-19%, and vomiting in 10-13% of patients

Oral administration is ineffective due to peptide degradation in the digestive system

Scientific Activity It binds a class B1 G-protein-coupled receptor and activates Gs, adenylyl cyclase, and cyclic AMP signaling in research assays